Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT02536508 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

627

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: BGF MDI 320/14.4/9.6 μg
DRUG: GFF MDI 14.4/9.6 μg
DRUG: BFF MDI 320/9.6 μg

Sponsor

Pearl Therapeutics, Inc.